128 related articles for article (PubMed ID: 1947761)
1. Serum tumour markers in clinical practice. Some general aspects.
Kvinnsland S
Scand J Clin Lab Invest Suppl; 1991; 206():6-11. PubMed ID: 1947761
[TBL] [Abstract][Full Text] [Related]
2. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
3. [Application of tumour markers in clinical practice].
Keuren JF; Thomas CM; Bonfrèr JM; Sweep CG; Boonstra JG
Ned Tijdschr Geneeskd; 2009; 153():A617. PubMed ID: 19857306
[TBL] [Abstract][Full Text] [Related]
4. Use of tumour markers in cancer diagnosis and treatment.
Higgins C
Nurs Times; 1996 Apr 17-23; 92(16):36-7. PubMed ID: 8710591
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the clinical use of tumour markers.
Duffy MJ
Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
[TBL] [Abstract][Full Text] [Related]
6. Tumour markers.
Pandha HS; Waxman J; Sikora K
Br J Hosp Med; 1994 Mar 16-Apr 5; 51(6):297-303. PubMed ID: 8032568
[TBL] [Abstract][Full Text] [Related]
7. [Criteria for using tumor markers. 2: Indications and interpretation].
Fateh-Moghadam VA; Stieber P
Fortschr Med; 1996 Mar; 114(7):38-40. PubMed ID: 8900968
[No Abstract] [Full Text] [Related]
8. How the measurements of a few serum markers can be combined to enhance their clinical values in the management of cancer.
Cordero OJ; De Chiara L; Lemos-González Y; Páez de la Cadena M; Rodríguez-Berrocal FJ
Anticancer Res; 2008; 28(4C):2333-41. PubMed ID: 18751415
[TBL] [Abstract][Full Text] [Related]
9. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
[TBL] [Abstract][Full Text] [Related]
10. [Tumor markers--how they should be applied].
Stieber P; Heinemann V; Schalhorn A
MMW Fortschr Med; 2005 May; 147(20):35, 37-9. PubMed ID: 15957858
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour markers in ovarian tumours.
von Schlippe M; Rustin GJ
Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers: their use and misuse by clinicians.
McGinley PJ; Kilpatrick ES
Ann Clin Biochem; 2003 Nov; 40(Pt 6):643-7. PubMed ID: 14629802
[TBL] [Abstract][Full Text] [Related]
13. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
14. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
15. [Tumour markers in malignant diseases].
Ottó S; Ferencz A
Magy Onkol; 2004; 48(1):13-20. PubMed ID: 15105891
[TBL] [Abstract][Full Text] [Related]
16. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
Lindmark G; Kressner U; Bergström R; Glimelius B
Anticancer Res; 1996; 16(2):895-8. PubMed ID: 8687147
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of molecular markers of oral cancer--a review.
Schliephake H
Int J Oral Maxillofac Surg; 2003 Jun; 32(3):233-45. PubMed ID: 12767868
[TBL] [Abstract][Full Text] [Related]
18. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of tumour markers.
Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
[TBL] [Abstract][Full Text] [Related]
20. Nuclear mitotic apparatus protein (NuMA) in benign and malignant diseases.
Hasholzner U; Stieber P; Zimmermann A; Burges A; Hofmann K; Schmitt UM; Schmeller N; Schalhorn A
Anticancer Res; 1999; 19(4A):2415-20. PubMed ID: 10470168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
